GO:0045056 transcytosis: Vesicular Transport Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045056 transcytosis is the directed movement of endocytosed material through a cell and its exocytosis at the opposite plasma membrane domain.
• Transcytosis is essential at the blood-brain barrier, in arterial endothelium, and in epithelial tissue morphogenesis.
• Key molecular players include caveolin-1 (CAV1), the LDL receptor (LDLR), the neonatal Fc receptor (FCGRT), and clathrin-associated machinery.
• Dysregulated transcytosis contributes to atherosclerosis, neurodegeneration, and tumor drug delivery barriers.
• CRISPR knockout, knock-in, and overexpression models enable causal testing of transcytosis genes in endothelial and epithelial cells.
• Quantitative imaging, proteomics, and CRISPR library screening are core methods for dissecting transcytosis pathways.
Description
Transcytosis (GO:0045056) is a specialized vesicular transport process in which endocytosed cargo is moved across a cell and released at the opposite plasma membrane surface. Unlike recycling or degradation pathways, transcytosis establishes directional transport across polarized cells, including endothelial and epithelial barriers. This process is fundamental for nutrient delivery, immune surveillance, and drug distribution, and it is a major route for macromolecules that cannot diffuse across cell membranes. Researchers study transcytosis to understand barrier biology, to design brain-penetrant therapeutics, and to explain how lipoproteins and nanoparticles reach tissues. Because transcytosis is tightly regulated and cell-type specific, genetic tools such as CRISPR are increasingly used to identify the genes that control it.
transcytosis At A Glance
| GO ID | GO:0045056 |
|---|---|
| GO term | transcytosis |
| Ontology | biological_process |
| Synonym | none |
| Major function | Directed transcellular transport of endocytosed cargo followed by exocytosis at the opposite plasma membrane domain |
| Cellular context | Polarized endothelial and epithelial cells, including the blood-brain barrier and arterial endothelium |
| Key cargo examples | LDL, therapeutic antibodies, nanoparticles, and plasma proteins |
| Regulatory theme | Lipid transport and caveolae-dependent signaling modulate transcytosis rates |
What Is GO:0045056?
According to the Gene Ontology, GO:0045056 transcytosis is defined as the directed movement of endocytosed material through the cell and its exocytosis from the plasma membrane at the opposite side. In other words, a cargo molecule is taken up on one face of a cell, trafficked across the cytoplasm in membrane-bound carriers, and secreted on the other face without being degraded.
Why Is transcytosis Important in Cell Biology?
Transcytosis is a central mechanism for moving large molecules across cellular barriers that otherwise block diffusion. It controls how lipoproteins enter arterial walls, how antibodies and nanoparticles reach the brain, and how epithelial tissues shape themselves during development. Because transcytosis is dysregulated in atherosclerosis and neurodegeneration, and because it limits drug delivery to tumors and the central nervous system, understanding its genetic control has direct therapeutic relevance.
• Enables LDL transport across arterial endothelium, a key step in atherosclerosis initiation.
• Regulates blood-brain barrier permeability and brain uptake of therapeutic antibodies.
• Supports epithelial tissue morphogenesis and lumen formation during development.
• Controls nanoparticle extravasation and tumor nanomedicine delivery.
• Is suppressed by lipid transport-dependent regulation of caveolae-mediated transcytosis.
• Provides a target for engineering brain-penetrant biologics via receptor affinity tuning.
• Links endothelial dysfunction to cardiovascular disease progression.
• Offers a mechanistic explanation for how circulating proteins reach tissue compartments.
• Can be studied with CRISPR screens to identify novel regulators.
• Is relevant to both normal physiology and multiple human diseases.
What Happens During transcytosis?
Endocytic uptake at the donor membrane
In simple terms: The cell grabs cargo on one side.
Transcytosis begins when cargo binds receptors or membrane domains at the donor plasma membrane and is internalized into vesicles. In endothelial cells, this uptake can occur through caveolae, clathrin-coated pits, or other endocytic routes depending on the cargo and cell type. For example, LDL is taken up by arterial endothelial cells as an early step in transcytosis.
Intracellular trafficking across the cell
In simple terms: The cargo travels through the cell in membrane packets.
After internalization, transcytotic carriers move through the cytoplasm while avoiding lysosomal degradation. This trafficking is directed and can involve sorting endosomes and specialized vesicular intermediates. The route is cell-type specific and is influenced by lipid composition and signaling state.
Exocytosis at the opposite membrane
In simple terms: The cargo is released on the other side of the cell.
The final step is fusion of transcytotic vesicles with the opposite plasma membrane domain, releasing cargo into the target compartment. This step establishes the directionality that defines transcytosis and distinguishes it from recycling or degradation. In the blood-brain barrier, this exocytosis delivers cargo into the brain parenchyma.
Regulation by lipid transport and caveolae
In simple terms: Fat transport signals can turn transcytosis up or down.
Lipid transport-dependent pathways suppress caveolae-mediated transcytosis at the blood-brain barrier, showing that transcytosis is actively regulated rather than constitutive. This regulation affects barrier permeability and can be perturbed in disease. Caveolae and their structural proteins are therefore central to transcytosis control.
Transcytosis in epithelial morphogenesis
In simple terms: Transcytosis helps tissues build their shape.
During epithelial development, transcytosis contributes to the delivery of material to growing surfaces and to the organization of polarized tissues. This role links transcytosis to morphogenesis and tissue architecture. It also highlights that transcytosis is not limited to endothelial barriers.
Key Genes Involved in GO:0045056 transcytosis
The following genes and proteins have documented roles in transcytosis or its regulation across endothelial and epithelial systems.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CAV1 | Caveolae structural protein involved in caveolae-mediated transcytosis | Knockout models to test caveolae-dependent transport |
| LDLR | Receptor for LDL uptake and transcytosis across arterial endothelium | Point mutations to dissect ligand binding versus transport |
| FCGRT | Neonatal Fc receptor that mediates antibody transcytosis | Affinity engineering to boost brain uptake |
| ALB | Carrier protein whose transport is relevant to endothelial transcytosis | Overexpression and tagged knock-in for trafficking studies |
| CLTC | Clathrin heavy chain involved in clathrin-mediated endocytic routes | Knockout to test clathrin-dependent transcytosis |
| RAB5A | Early endosomal GTPase implicated in endocytic sorting | Knock-in of tagged RAB5A for live imaging |
| RAB7A | Late endosomal GTPase that can influence transcytotic sorting | Knockout to assess degradation versus transcytosis |
| RAB11A | Recycling endosome GTPase relevant to transcytotic carriers | Overexpression to enhance transport |
| VAMP3 | SNARE protein involved in vesicle fusion events | Knockout to test exocytosis step |
| SNAP23 | SNARE protein participating in membrane fusion | Point mutation to disrupt fusion |
| STX4 | Plasma membrane SNARE for vesicle docking | Knock-in for localization studies |
| ARF6 | Small GTPase regulating endosomal recycling and transcytosis | Knockout to test pathway dependence |
| PICALM | Clathrin assembly protein in endocytosis | Knockout to probe uptake route |
| DNM2 | Dynamin GTPase required for vesicle scission | Point mutation to block scission |
| ACTB | Actin cytoskeleton supporting vesicle movement | Overexpression for cytoskeletal studies |
| MYH9 | Myosin motor involved in vesicle transport | Knockout to test motor dependence |
| CD36 | Scavenger receptor linked to endothelial lipid transport | Knockout to test LDL transcytosis |
| SCARB1 | Scavenger receptor BI in lipoprotein handling | Overexpression to modulate uptake |
How Is transcytosis Regulated?
Transcytosis is regulated by lipid transport-dependent signaling that suppresses caveolae-mediated transport at the blood-brain barrier. This regulation controls barrier permeability and can be altered in disease states. In arterial endothelium, LDL transcytosis is modulated by receptor availability and endothelial signaling, making it a therapeutic target. The process is also influenced by the endosomal sorting machinery and SNARE-mediated fusion events that determine whether cargo is transported or degraded.
transcytosis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Atherosclerosis and LDL transcytosis | Endothelial knockout and point-mutation models |
| CAV1 | Blood-brain barrier permeability and caveolae-mediated transcytosis | Knockout and overexpression in brain endothelial cells |
| FCGRT | Antibody brain uptake and therapeutic delivery | Knock-in with affinity variants |
| CD36 | Endothelial lipid transport and atherosclerosis | Knockout in arterial endothelial cells |
| SCARB1 | Lipoprotein handling and cardiovascular risk | Overexpression and knockout models |
Atherosclerosis and cardiovascular disease
LDL transcytosis across arterial endothelium is an early step in atherosclerosis, and targeting this process is considered a therapeutic strategy. Dysregulated endothelial transcytosis contributes to lipid accumulation in the vessel wall. Understanding the genes that control LDL transcytosis may reveal new intervention points.
Blood-brain barrier dysfunction and neurodegeneration
Transcytosis at the blood-brain barrier regulates brain uptake of molecules, and its dysregulation is linked to barrier permeability changes in neurological disease. Lipid transport-dependent suppression of caveolae-mediated transcytosis is a key regulatory node. Therapeutic antibodies can be engineered to exploit transcytosis for brain delivery.
Cancer and tumor drug delivery
Transcytosis-enabled active extravasation of tumor nanomedicine is a mechanism by which nanoparticles cross tumor vasculature. This process influences how effectively drugs reach tumor cells. Modulating transcytosis could improve nanomedicine design.
Epithelial morphogenesis and developmental disorders
Transcytosis contributes to epithelial tissue development and morphogenesis, and its disruption may affect tissue architecture. This role connects transcytosis to developmental biology and tissue engineering.
From transcytosis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is CAV1 required for caveolae-mediated transcytosis? | CAV1 knockout endothelial cells |
| Does LDLR point mutation alter LDL transcytosis? | LDLR point-mutation knock-in |
| Can FCGRT affinity tuning increase brain uptake? | FCGRT knock-in with engineered variants |
| Where does a candidate protein localize during transcytosis? | Tagged knock-in with fluorescent tag |
| Does overexpression of RAB11A enhance transport? | RAB11A overexpression in polarized cells |
| Which genes regulate transcytosis in a genome-wide screen? | CRISPR library screening in endothelial cells |
How to Study the transcytosis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell imaging | Vesicle movement and exocytosis events | Tracking transcytotic cargo in polarized cells |
| Proteomics | Protein composition of transcytotic carriers | Identifying novel regulators |
| CRISPR knockout screen | Genes required for transcytosis | Genome-wide discovery in endothelial cells |
| Labeled cargo transport assay | Rate and direction of transcytosis | Testing LDL or antibody transport |
| RNA-seq | Transcriptional changes after perturbation | Validating pathway responses |
| Immunofluorescence | Subcellular localization of proteins | Confirming trafficking defects |
| Co-immunoprecipitation | Protein-protein interactions | Mapping transcytosis complexes |
| Nanoparticle extravasation assay | Tumor delivery via transcytosis | Evaluating nanomedicine transport |
Quantitative imaging of transcytosis
Live-cell and fixed-cell imaging with fluorescent cargo or tagged proteins allows direct visualization of uptake, trafficking, and exocytosis steps. Polarized cell culture systems are used to measure directional transport. These methods are essential for confirming that a gene perturbation alters transcytosis rather than general endocytosis.
Proteomics and interactome analysis
Proteomic profiling of transcytotic vesicles and their cargo can identify new regulators and cargo receptors. Affinity purification of tagged proteins followed by mass spectrometry reveals interaction partners. These approaches complement genetic screens by providing mechanistic context.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that enhance or suppress transcytosis. Such screens are powerful for discovering novel regulators in endothelial and epithelial cells. Hits can then be validated with targeted knockout or knock-in models.
Transport assays with labeled cargo
Labeled LDL, antibodies, or nanoparticles are used to measure transcytosis rates across cell monolayers. These assays quantify directional transport and can be combined with genetic perturbations. They are widely used in blood-brain barrier and arterial endothelium research.
How CRISPR Can Be Used to Study GO:0045056 transcytosis
Knockout
CRISPR knockout of candidate genes such as CAV1, LDLR, or RAB GTPases allows direct testing of their requirement for transcytosis. Knockout endothelial cells can be assayed for directional transport of labeled cargo. This approach is foundational for causal inference in transcytosis research.
Point Mutation
Point mutations can dissect specific domains or residues involved in cargo binding, vesicle scission, or fusion. For example, LDLR point mutants can separate ligand binding from transcytosis capacity. This precision is valuable when complete knockout is lethal or pleiotropic.
Knock-in
Knock-in of fluorescent or affinity tags enables real-time tracking of transcytosis proteins and their complexes. Knock-in of engineered receptor variants, such as FCGRT affinity mutants, can optimize brain uptake. Tagged knock-in models preserve endogenous regulation while enabling visualization.
Overexpression
Overexpression of genes such as RAB11A or SCARB1 can enhance or perturb transcytosis and reveal rate-limiting steps. Overexpression models are useful for gain-of-function studies and for testing therapeutic hypotheses. They complement knockout approaches by probing sufficiency.
How EDITGENE Supports transcytosis Research
Researchers studying transcytosis-related genes often need to determine whether a candidate gene is causally involved in cargo transport, barrier permeability, or disease progression. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations in endothelial and epithelial systems, helping teams move from correlation to causation in transcytosis research.
Contact EDITGENE today to design your custom CRISPR model for transcytosis research.
Frequently Asked Questions About transcytosis
What is transcytosis GO:0045056?
Transcytosis is the directed movement of endocytosed material through a cell and its exocytosis at the opposite plasma membrane, as defined by GO:0045056.
What genes are involved in transcytosis?
Key genes include CAV1, LDLR, FCGRT, RAB5A, RAB7A, RAB11A, and SNARE proteins such as VAMP3 and SNAP23.
Why is transcytosis important at the blood-brain barrier?
It regulates brain uptake of molecules and therapeutic antibodies, and its dysregulation affects barrier permeability.
How is transcytosis studied experimentally?
Common methods include labeled cargo transport assays, live-cell imaging, proteomics, and CRISPR screens.
What is the role of caveolae in transcytosis?
Caveolae mediate a major route of transcytosis, and lipid transport-dependent pathways suppress caveolae-mediated transport.
Can transcytosis be targeted for drug delivery?
Yes, transcytosis-enabled extravasation is exploited for tumor nanomedicine and engineered antibodies for brain delivery.
Which diseases involve defective transcytosis?
Atherosclerosis, blood-brain barrier dysfunction, neurodegeneration, and cancer drug delivery barriers are linked to transcytosis.
What is LDL transcytosis?
LDL transcytosis is the transport of LDL across arterial endothelium, an early step in atherosclerosis.
How do CRISPR models help transcytosis research?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of candidate genes in transport assays.
What is the difference between endocytosis and transcytosis?
Endocytosis is uptake into the cell, while transcytosis includes uptake, intracellular trafficking, and exocytosis at the opposite membrane.
Conclusion
GO:0045056 transcytosis is a directional vesicular transport process that moves cargo across polarized cells and is central to barrier biology, lipoprotein handling, and therapeutic delivery. Its dysregulation contributes to atherosclerosis, blood-brain barrier dysfunction, and tumor drug delivery challenges. CRISPR-based models and functional screens provide powerful tools to dissect the genes and mechanisms controlling transcytosis, supporting both basic discovery and translational applications.
References
- 1. Jones JH et al.. 2020. Lung Endothelial Transcytosis.. Compr Physiol 10(2):491-508 PMID: 32163197
- 2. Bolanle IO et al.. 2025. Transcytosis of LDL Across Arterial Endothelium: Mechanisms and Therapeutic Targets.. Arterioscler Thromb Vasc Biol 45(4):468-480 PMID: 40013359
- 3. Zhou Q et al.. 2022. Transcytosis-enabled active extravasation of tumor nanomedicine.. Adv Drug Deliv Rev 189:114480 PMID: 35952830
- 4. Ayloo S et al.. 2019. Transcytosis at the blood-brain barrier.. Curr Opin Neurobiol 57:32-38 PMID: 30708291
- 5. Ho TWW et al.. 2023. LDL Transcytosis by the Arterial Endothelium-Atherosclerosis by a Thousand Cuts?. Curr Atheroscler Rep 25(8):457-465 PMID: 37358804
- 6. Yu YJ et al.. 2011. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.. Sci Transl Med 3(84):84ra44 PMID: 21613623
- 7. Serra ND et al.. 2021. Transcytosis in the development and morphogenesis of epithelial tissues.. EMBO J 40(9):e106163 PMID: 33792936
- 8. Andreone BJ et al.. 2017. Blood-Brain Barrier Permeability Is Regulated by Lipid Transport-Dependent Suppression of Caveolae-Mediated Transcytosis.. Neuron 94(3):581-594.e5 PMID: 28416077
